Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Annual Report 2025



The latest annual report of Dr. Reddy's Laboratories Limited (DRREDDY) was published on 31 Mar 2025. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - DRREDDY Annual Results

Amounts in INR

Total Revenue
₹325.54B
Gross Profit
₹190.84B
EBIT
₹56.79B
Net Tangible Assets
₹372.37B
Net Income
₹56.54B
Capital Expenditures
-

DRREDDY Income Statement 2025 Annual Report

As per the latest Income Statement of DRREDDY, the Net revenue increased by ₹46.37B (17%) compared to the previous period. The operating income in 2025 increased by - (-). The net income as per the annual report was ₹56.54B which increased by ₹765.00M (1%) compared to previous year.

Income Statement Report (2025/2024)

2025 2024
Total Revenue ₹325.54B ₹279.16B
Gross Profit ₹190.84B ₹190.84B
Operating Income - -
Income Before Tax - -
Net Income ₹56.54B ₹55.78B

Balance Sheet - DRREDDY 2025 Annual Report

Read further: DRREDDY Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Dr. Reddy's Laboratories Limited showed the company increased the cash on balance sheet by ₹0.00 (0%). The Net tangible assets of DRREDDY on the balance sheet were at ₹372.37B which is ₹0.00 (0%) more than previous annual report. The total stockholder equity also increased by - (-) compared to previous reporting period.

Balance Sheet Statement Report (2025/2024)

2025 2024
Cash ₹82.59B ₹82.59B
Total Assets - -
Long Term Debt - -
Total Liabilities ₹67.73B ₹67.73B
Total Shareholder Equity - -
Net Tangible Assets ₹372.37B ₹372.37B

Cash Flow Statement - DRREDDY 2025 Annual Report

The 2025 annual cash flow statement of Dr. Reddy's Laboratories Limited showed that the net income increased by ₹765.00M (1%) compared to previous reporting period. Also the capital expenditure of DRREDDY increased by - (-).

As of 2025, the total cash from investing activities was - and total cash from financing activities was -.

Cash Flow Statement Report (2025/2024)

2025 2024
Net Income ₹56.54B ₹55.78B
Capital Expenditures - -
Dividends Paid - -
Total Cash From From Investing Activities - -
Total Cash From From Financing Activities - -

Dr. Reddy's Laboratories Limited Annual Report History

Income Statement

Income Statement history of Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

31 Mar 2025 31 Mar 2024 31 Mar 2023 31 Mar 2022
Total Revenue ₹325.54B ₹279.16B ₹246.70B ₹214.39B
Cost Of Revenue ₹0.00 ₹0.00 ₹0.00 ₹0.00
Gross Profit ₹0.00 ₹0.00 ₹0.00 ₹0.00
Research Development - - - -
Selling General Administrative - - - -
Non Recurring - - - -
Other Operating Expenses - - - -
Total Operating Expenses ₹0.00 ₹0.00 ₹0.00 ₹0.00
Operating Income - - - -
Total Other Income Expense Net - - - -
Ebit ₹0.00 ₹0.00 ₹0.00 ₹0.00
Interest Expense - - - -
Income Before Tax - - - -
Income Tax Expense ₹0.00 ₹0.00 ₹0.00 ₹0.00
Minority Interest - - - -
Net Income From Continuing Ops - - - -
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income ₹56.54B ₹55.78B ₹45.07B ₹23.57B
Net Income Applicable To Common Shares - - - -

Balance Sheet Statement

Balance Sheet Statement history of Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

31 Mar 2025 31 Mar 2024 31 Mar 2023 31 Mar 2022
Cash ₹82.59B ₹82.59B - -
Total Assets - - - -
Total Liab ₹67.73B ₹67.73B - -
Long Term Debt - - - -
Total Stockholder Equity - - - -
Net Tangible Assets ₹372.37B ₹372.37B - -

Cash Flow Statement

Cash Flow Statement history of Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

31 Mar 2025 31 Mar 2024 31 Mar 2023 31 Mar 2022
Net Income ₹56.54B ₹55.78B - -
Capital Expenditures - - - -
Dividends Paid - - - -
Total Cashflows From Investing Activities - - - -
Total Cash From Financing Activities - - - -